BSSP News
Reve Announces Closing Exclusive License for Cantecks IPF Irreversable Pepsin Fraction Specificto Cancer Indication Only, For Mexico
Moves Ahead On Its Immunotherapeutic IPF Platform Technology for Development, Manufacture and Commercialization
MONROVIA, CA / ACCESSWIRE / May 10, 2016 / Reve Technologies, Inc. (OTCPK: BSSP) (the "Company" or "Reve") a development stage technology company is pleased to announce it has effectively closed on its Purchase and Sale Agreement (the "Purchase Agreement") with Canteck Pharma, Inc., a Delaware corporation ("Canteck" or "CKPH") and certain majority shareholders of CKPH. Canteck has developed and has patented technology (US 8,067,531 B2) and also known as Irreversible Pepsin Fraction ("IPF"). The parties will continue to deliver post closing requirements. The IPF is a therapeutic platform technology that can be used to facilitate a broad range of applications. It is free from neurological, gastrointestinal and hematological side effects. IPF has not shown to be subject to viral resistance and is cost effective.
As previously reported the Purchase Agreement sets forth the plan through which the Company acquires One Hundred Percent (100%) ownership Interest in Canteck Pharma, Inc. for its current and planned operations and the exclusive Sub Licensing Agreement for Irreversible Pepsin Fraction specific to the Cancer indication only, for Mexico. In recent developments the Company reports it has obtained its import export license with Mexico and has been informed by third parties involved in the permitting processes with hospitals in Mexico that it can expect its initial permitting will become effective by the end of May 2016 for the Company to commence sales.
"We are pleased with our closing processes with Canteck for immunotherapeutic technology for certain designated Cancer indications," said Dennis Alexander, CEO of the Company. "Further, the Company looks forward to address the synergies and management cultures, changing and adopting our name to Cantech Holding, Inc., thus building upon the progress that our colleagues at Canteck and now the Company have achieved in creating a portfolio of innovative oncology technologies that we believe adds significant value through its R&D strengths."
"We are excited on our completing closing processes and believe this transaction is a major step towards our mutual goal of producing durable outcomes in oncology to develop and commercialize our immune-oncology based IPF treatment as a new therapy for difficult-to-treat tumor indications on a scalable international level initially Mexico." Said Mr. Harry Zhabilov, Jr. BSc, McS and newly appointed Chief Scientist of the Company. "We look forward to working together to obtain permit approvals shortly for our IPF Irreversible Pepsin Fraction specific to the Cancer indication, and to bring these much-needed therapeutic options as soon as possible for delivery and availability to Mexico and together advance both companies' towards clinical programs planned ahead in new markets."
About Canteck Pharma, Inc. IPF for Cancer treatment
Immunotherapy has the potential to provide an alternative and/or complementary treatment for most types of cancer. The advantage of immunotherapy over radiation and chemotherapy is that it can act specifically against the tumor without causing normal tissue damage. Current data indicates that immune protection against all cancer requires the generation of a potent cellular immune response against a unique tumor antigen expressed by the malignant cell. As a consequence successful immune protection first requires a unique antigen expressed in the tumor cells (tumor specific antigen) and second, an induction of a potent T-cell immune response, targeted to the tumor antigen.
Unfortunately the immune system by itself can´t recognize specific tumor antigens and reject them; however recent advances have revealed that certain proteins binding with specific tumor antigens can be recognized by the immune system, this is what IPF does.
IPF proteins attach to tumor antigens, creating superantigens (Sags), which increases the number of antibodies against the malignant cells and induces a potent T-cell immune response targeted to the tumor antigen. For a stronger immune response, IPF may be paired with different kinds of adjuvants such as IL-2, IL-6, IL-12 or other cytokines. Another form of immunotherapy can also provide active immunization, which allows for amplification of the immune response. In addition, vaccines can generate a memory immune response. Recent advances have revealed that any cellular protein (expressed in virally infected cells or cancer cells) can be recognized by the immune system if those proteins are presented to the immune system in a form that results in an activation rather than ignorance or tolerance to the antigen. In addition, T-cells rather than B-cells are usually responsible for this recognition.
It is important to point out that when we discuss vaccines for cancer we are referring to treatment rather than prevention, because the antigens expressed by tumor cells (which are the immunogens recognized by the immune system) are not yet known. Attaching known proteins will increase the number of antibodies to fight against them.
This mechanism of action will give us an exact answer (known antigens we have to make known for immune system). In contrast we can use vaccines to prevent infectious diseases because the antigens expressed the causative agent - fraction and/or its proteins that can attach, serve as the immunogen are already known.
About Reve Technologies, Inc.
The Company was incorporated on May 11, 2010 (Date of Inception) under the laws of the State of Nevada, as Bassline Productions, Inc. On March 21, 2014 the Company amended its articles of incorporation and changed its name to Reve Technologies, Inc. and investing to develop and market emerging hardware, mobile and web applications later establishing a new Capital Purchase Division. The Company is now a transitioning forward with the acquisition of an Exclusive License Agreement for Patented Technology for Irreversible Pepsin Fraction (IPF) specific to the Cancer indication only, for Mexico with privately held immune-oncology and Therapeutics company. Through the terms for the Company's Exclusive Sub Licensing Agreement with Canteck Pharma, Inc. we will focus on the development, manufacture and commercialize our lead product Irreversible Pepsin Fraction (IPF) specific to the Cancer indication only, for Mexico, with options for other indications.
This release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Reve Technologies, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. The words "may," "would," "will," "expect," "estimate," "can," "believe," "potential" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Reve Technologies, Inc.'s ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is and will be included in Reve Technologies, Inc.'s filings with the Securities and Exchange Commission.
